Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial

By  Lise Jamieson  Celicia Serenata, Lebogang Makhubele, Simiso Sokhela, Nkuli Mashabane, Godspower Akpomiemie, Leigh F. Johnson, Willem D.F. Venter  Dr Gesine Meyer-Rath  |  | 

Though the DTG-based trial arms were 2% more costly than TDF/FTC/EFV, both had slightly lower cost-per-outcome ($9783 and $9929/patient virally suppressed for TDF/FTCþDTG and TAF/FTCþDTG, respectively) than TDF/FTC/EFV ($10 365). The trial cost per additional virally suppressed patient, compared with TDF/FTC/EFV, was lower in the TDF/FTCþDTG arm ($2967) compared with TAF/FTCþDTG ($3430). In routine care, cost per virally suppressed patient was estimated as similar between TDF/ FTCþDTG ($426) and TDF/FTC/EFV ($424) but more costly under TAF/FTCþDTG. Similar results were seen in the cost per additional person retained across scenarios. When modelled over 20 years, TDF/FTCþDTG was more cost-effective than TAF/ FTCþDTG ($10 341 vs $41 958/life-year saved)

Publication details

AIDS
#35
2021
PDF